Literature DB >> 25905443

Cytomegalovirus seropositivity is associated with herpes zoster.

Benson Ogunjimi1, Niel Hens, Richard Pebody, Hilde Jansens, Holly Seale, Mark Quinlivan, Heidi Theeten, Herman Goossens, Judy Breuer, Philippe Beutels.   

Abstract

Herpes zoster (HZ) is caused by VZV reactivation that is facilitated by a declined immunity against varicella-zoster virus (VZV), but also occurs in immunocompetent individuals. Cytomegalovirus (CMV) infection is associated with immunosenescence meaning that VZV-specific T-cells could be less responsive. This study aimed to determine whether CMV infection could be a risk factor for the development of HZ. CMV IgG serostatus was determined in stored serum samples from previously prospectively recruited ambulatory adult HZ patients in the UK (N = 223) in order to compare the results with those from UK population samples (N = 1545) by means of a logistic regression (controlling for age and gender). Furthermore, we compared the UK population CMV seroprevalence with those from population samples from other countries (from Belgium (N1 = 1741, N2 = 576), USA (N = 5572) and Australia (N = 2080)). Furthermore, CMV IgG titers could be compared between UK HZ patients and Belgium N2 population samples because the same experimental set-up for analysis was used. We found UK ambulatory HZ patients to have a higher CMV seroprevalence than UK population samples (OR 1.56 [1.11 2.19]). CMV IgG seropositivity was a significant risk factor for HZ in the UK (OR 3.06 [1.32 7.04]. Furthermore, high CMV IgG titers (exceeding the upper threshold) were less abundant in CMV-seropositive Belgian N2 population samples than in CMV-seropositive UK HZ patients (OR 0.51 [0.31 0.82]. We found CMV-seroprevalence to increase faster with age in the UK than in other countries (P < 0.05). We conclude that CMV IgG seropositivity is associated with HZ. This finding could add to the growing list of risk factors for HZ.

Entities:  

Keywords:  CMV; immunosenescence; reactivation; shingles; susceptibility; zoster

Mesh:

Substances:

Year:  2015        PMID: 25905443      PMCID: PMC4514428          DOI: 10.1080/21645515.2015.1037999

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  30 in total

1.  THE NATURE OF HERPES ZOSTER: A LONG-TERM STUDY AND A NEW HYPOTHESIS.

Authors:  R E HOPE-SIMPSON
Journal:  Proc R Soc Med       Date:  1965-01

2.  NIH conference. Herpes zoster-varicella infections in immunosuppressed patients.

Authors:  R Dolin; R C Reichman; M H Mazur; R J Whitley
Journal:  Ann Intern Med       Date:  1978-09       Impact factor: 25.391

3.  Are we hitting immunity targets? The 2006 age-specific seroprevalence of measles, mumps, rubella, diphtheria and tetanus in Belgium.

Authors:  H Theeten; V Hutse; N Hens; Y Yavuz; K Hoppenbrouwers; P Beutels; R Vranckx; P Van Damme
Journal:  Epidemiol Infect       Date:  2010-06-29       Impact factor: 2.451

4.  National serosurvey of cytomegalovirus in Australia.

Authors:  Holly Seale; C Raina MacIntyre; Heather F Gidding; J L Backhouse; Dominic E Dwyer; Lyn Gilbert
Journal:  Clin Vaccine Immunol       Date:  2006-09-06

5.  Cytomegalovirus infection and the risk of mortality and frailty in older women: a prospective observational cohort study.

Authors:  George C Wang; Wen Hong L Kao; Peter Murakami; Qian-Li Xue; Roger B Chiou; Barbara Detrick; John F McDyer; Richard D Semba; Vincenzo Casolaro; Jeremy D Walston; Linda P Fried
Journal:  Am J Epidemiol       Date:  2010-04-16       Impact factor: 4.897

Review 6.  The impact of CMV infection on survival in older humans.

Authors:  Graham Pawelec; Janet E McElhaney; Allison E Aiello; Evelyna Derhovanessian
Journal:  Curr Opin Immunol       Date:  2012-04-27       Impact factor: 7.486

Review 7.  What does epidemiology tell us about risk factors for herpes zoster?

Authors:  Sara L Thomas; Andrew J Hall
Journal:  Lancet Infect Dis       Date:  2004-01       Impact factor: 25.071

Review 8.  Role of cytomegalovirus (CMV) IgG avidity testing in diagnosing primary CMV infection during pregnancy.

Authors:  Harry E Prince; Mary Lapé-Nixon
Journal:  Clin Vaccine Immunol       Date:  2014-08-27

Review 9.  Herpes Zoster Risk Reduction through Exposure to Chickenpox Patients: A Systematic Multidisciplinary Review.

Authors:  Benson Ogunjimi; Pierre Van Damme; Philippe Beutels
Journal:  PLoS One       Date:  2013-06-21       Impact factor: 3.240

10.  Quantification of risk factors for herpes zoster: population based case-control study.

Authors:  Harriet J Forbes; Krishnan Bhaskaran; Sara L Thomas; Liam Smeeth; Tim Clayton; Sinéad M Langan
Journal:  BMJ       Date:  2014-05-13
View more
  5 in total

1.  Latency for cytomegalovirus impacts T cell ageing significantly in elderly end-stage renal disease patients.

Authors:  L Huang; A W Langerak; C C Baan; N H R Litjens; M G H Betjes
Journal:  Clin Exp Immunol       Date:  2016-08-19       Impact factor: 4.330

2.  Reduced NK cell IFN-γ secretion and psychological stress are independently associated with herpes zoster.

Authors:  Choon Kwan Kim; Youn Mi Choi; Eunsin Bae; Mihn Sook Jue; Hyung Seok So; Eung-Soo Hwang
Journal:  PLoS One       Date:  2018-02-21       Impact factor: 3.240

Review 3.  Benefit and Risk of Tofacitinib in the Treatment of Rheumatoid Arthritis: A Focus on Herpes Zoster.

Authors:  Kunihiro Yamaoka
Journal:  Drug Saf       Date:  2016-09       Impact factor: 5.228

4.  Increased herpes zoster risk associated with poor HLA-A immediate early 62 protein (IE62) affinity.

Authors:  Pieter Meysman; Nicolas De Neuter; Esther Bartholomeus; George Elias; Johan Van den Bergh; Marie-Paule Emonds; Geert W Haasnoot; Steven Heynderickx; Johan Wens; Nele R Michels; Julien Lambert; Eva Lion; Frans H J Claas; Herman Goossens; Evelien Smits; Pierre Van Damme; Viggo Van Tendeloo; Philippe Beutels; Arvid Suls; Geert Mortier; Kris Laukens; Benson Ogunjimi
Journal:  Immunogenetics       Date:  2017-12-01       Impact factor: 3.330

5.  Multidisciplinary study of the secondary immune response in grandparents re-exposed to chickenpox.

Authors:  B Ogunjimi; J Van den Bergh; P Meysman; S Heynderickx; K Bergs; H Jansens; E Leuridan; A Vorsters; H Goossens; K Laukens; N Cools; Viggo Van Tendeloo; N Hens; P Van Damme; Evelien Smits; Ph Beutels
Journal:  Sci Rep       Date:  2017-04-24       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.